Development of resveratrol-curcumin hybrids as potential therapeutic agents for inflammatory lung diseases
作者:Jialing Pan、Tingting Xu、Fengli Xu、Yali Zhang、Zhiguo Liu、Wenbo Chen、Weitao Fu、Yuanrong Dai、Yunjie Zhao、Jianpeng Feng、Guang Liang
DOI:10.1016/j.ejmech.2016.09.033
日期:2017.1
Acute lung injury (ALI) is a major cause of acute respiratory failure in critically-ill patients. Resveratrol and curcumin are proven to have potent anti-inflammatory efficacy, but their clinical application is limited by their metabolic instability. Here, a series of resveratrol and the Mono-carbonyl analogs of curcumin (MCAs) hybrids were designed and synthesized by efficient aldol construction strategy
急性肺损伤(ALI)是危重患者急性呼吸衰竭的主要原因。已证实白藜芦醇和姜黄素具有有效的抗炎功效,但其临床应用受到其代谢不稳定的限制。此处,一系列白藜芦醇和姜黄素的单羰基类似物(的MCA)杂交种设计和高效的羟醛构建策略合成,然后筛选抗炎活性在体外和体内。结果表明,大多数类似物有效抑制了LPS诱导的IL-6和TNF-α的产生。五个类似物a9,a18,a19,a20和a24以剂量依赖的方式表现出出色的抗炎活性以及低毒性体外。结构活性关系研究表明,苯环对位的吸电子基团和苯环对位的甲氧基(OCH 3)对消炎活性很重要。最有希望的化合物a18降低LPS诱导的TNF-α,IL-6,IL-12和IL-33 mRNA表达。此外,在体内小鼠模型中,a18显着保护免受LPS诱导的急性肺损伤。白藜芦醇和MCA杂种的研究可以为炎症性疾病的治疗带来见识,化合物a18可以作为抗ALI药物开发的先导化合物。